Jean-Francois Geschwind

This inventor holds 7 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Johns Hopkins University. Active years: 2009-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Francois Geschwind. Retrieved from https://idiyas.com/inventor/jean-francois-geschwind

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 5)

% Patents Active = 85.7

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 3.1

ph-index = 3

Forward Citations = 14(Granted Patents)

Location History:

Potomac, MD (US) (2009 - 2017)
Potoman, MD (US) (2018)
Westport, CT (US) (2020 - 2022)

Company Filing History:

7 out of 3,803

Johns Hopkins University

patents

Years Active: 2009-2022

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11241402 - Methods of treating liver fibrosis by administering 3-bromopyruvate (2022-02-08),

2. 10751306 - Methods of treating liver fibrosis by administering 3-bromopyruvate (2020-08-25),

3. 10130598 - Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer (2018-11-20),

4. 9737487 - Cyclodextrin compositions encapsulating a selective ATP inhibitor and uses thereof (2017-08-22),

5. 9492417 - Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer (2016-11-15),

6. 8119116 - Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production (2012-02-21),

7. 7547673 - Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production (2009-06-16),

Title: Innovations by Jean-Francois Geschwind

Introduction

Jean-Francois Geschwind is a notable inventor based in Potomac, MD (US). He has made significant contributions to the field of medical science, particularly in the treatment of liver fibrosis. With a total of 7 patents to his name, his work has the potential to impact many lives.

Latest Patents

One of his latest patents focuses on methods of treating liver fibrosis by administering 3-bromopyruvate. This patent outlines methods for treating or preventing liver fibrosis in a subject by administering a therapeutically effective amount of 3-bromopyruvate (3-BrPA). Additionally, it provides methods for promoting the reversal of an activated hepatic stellate cell (HSC) to an inactivated HSC by contacting the activated HSC with at least one 3-bromopyruvate (3-BrPA) molecule.

Career Highlights

Jean-Francois Geschwind is affiliated with The Johns Hopkins University, where he continues to advance his research and innovations. His work is recognized for its potential to change the landscape of liver disease treatment.

Collaborations

He has collaborated with notable colleagues such as Shanmugasundaram Ganapathy-Kanniappan and Surojit Sur, contributing to a rich environment of innovation and research.

Conclusion

Jean-Francois Geschwind's contributions to the field of liver fibrosis treatment exemplify the impact of dedicated research and innovation. His patents and collaborations highlight the importance of scientific advancement in improving health outcomes.

Profile summary based on public USPTO records.